Issue Date: March 20, 2017
eGenesis launches to overhaul transplants
Xenotransplantation-focused eGenesis has secured $38 million in its first round of financing. The biotech firm plans to use the gene-editing technology CRISPR to engineer pig cells to grow human-transplantable cells, tissues, and organs. eGenesis was founded by renowned Harvard Medical School geneticist George Church and his former postdoctoral researcher Luhan Yang, who developed a way to use CRISPR to get rid of pathogenic factors in pig cells. Yang now serves as eGenesis’s chief scientific officer.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society